Kymera Investor Day Presentation Deck

STAT3 Degrader KT-333, First-in-class Opportunity to Address STAT3-driven Pathology Across Diverse Indications • First heterobifunctional degrader against an undrugged target in the clinic • Profound single agent activity in liquid tumor and promising combo activity with anti-PD1 in liquid and solid tumors. Clinical development strategy includes direct registrational path in STAT3 pathway activated heme malignancies Opportunity for expansion into solid tumors in combination with immune checkpoint inhibitors KYMERA ©2021 KYMERA THERAPEUTICS, INC. KYMERA R&D DAY - December 16th, 2021 PAGE 66

View entire presentation